オプションチェーンは、Invivydの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Invivydの市場センチメントを評価します。.

Invivyd (NASDAQ:IVVD) 株価情報, オプションチェーン

Invivyd

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Invivyd Inc

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Origin Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBK#NYSE">OBK</a>) with a Outperform and lowers the price target from $44 to $41.

News

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Outperform on Origin Bancorp, Lowers Price Target to $41

<ul>
<li>Plans to introduce hydrogen trucks to Southern California-based Toyota North American Parts Center fleet</li>
<li>Investments in hydrogen infrastructure to benefit trucking fleets and consumers</li>
<li>North American debut of Toyota's more efficient, more powerful Gen 3 FC system</li>
</ul>
&nbsp;Toyota Motor North America (Toyota) today reaffirmed its commitment to a Hydrogen Society at the 2025 Advanced Clean Transportation Expo, introducing hydrogen-related plans, investments and debuting new fuel cell technologies and products.
At a keynote during the ACT Expo's Hydrogen Workshop, Toyota Group Vice President of Powertrain Engineering Jordan Choby announced plans to introduce hydrogen-powered fuel cell electric Class 8 heavy-duty trucks as part of an effort to reduce the number of diesel-powered tractor trailers servicing Toyota's North America Parts Center California (NAPCC). To support the new hydrogen trucks in the fleet, the company also announced plans for a new hydrogen fueling station to be built on the NAPCC campus, as well as plans to further invest and vertically integrate into the hydrogen ecosystem.
Toyota also debuted its next-generation fuel cell technology in North America, the Toyota Gen 3 FC system.
"Hydrogen as a fuel – and especially fuel cells – offer benefits that can make a positive change, and we are invested in their long-term success," Choby said. "We are investing in resources that we believe will lead to sustainable growth, both for our operations and the entire value chain in this still-evolving transportation sector."
With Class 8 heavy-duty trucks powered by fuel cells moving out of their pilot phase, Toyota will begin introducing production-level FCEV trucks to its logistics fleet, running routes from the Port of Long Beach to the NAPCC in Ontario, California, and even as far south as San Diego. The shift is part of Toyota's <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4414566-1&amp;h=1490518336&amp;u=https%3A%2F%2Fwww.toyota.com%2F2050challenge%2F&amp;a=2050+Challenge">2050 Challenge</a> goal of reducing carbon dioxide emissions from its supply chain.
"Our goals, capabilities to accomplish those goals and long-term mindset have put Toyota in a position to be a leader moving the global transportation industry forward," Choby said.
To bring its plans to life, Toyota is working with Air Liquide and Iwatani to strengthen fueling infrastructure. With Iwatani, there is an additional focus on commercial vehicles for a state-of-the-art station using new liquid hydrogen technology and SAE J2601/5-capable high-flow fueling systems. The high-flow system enables faster fueling than conventional hydrogen fueling stations, comparable in fueling time with diesel fuel pumps, and especially useful to fleet and commercial customers in helping improve operational uptime.
Toyota and Air Liquide will work together on sourcing and delivering hydrogen molecules from Air Liquide's dedicated hydrogen mobility plant in North Las Vegas, Nevada, with a focus on supplying the NAPCC station with reliable, affordable liquid hydrogen.
Toyota will also look to build relationships with other companies and organizations in the U.S. as well as those abroad.
In Japan, Toyota Motor Corporation is <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4414566-1&amp;h=4063463343&amp;u=https%3A%2F%2Fglobal.toyota%2Fen%2Fnewsroom%2Fcorporate%2F40388622.html&amp;a=collaborating+with+Chiyoda">collaborating with Chiyoda</a> on electrolysis technology, where they are combining their respective expertise in industrial products and plant engineering. Electrolyzers are devices capable of splitting water molecules into hydrogen and oxygen, the process to generate hydrogen fuel. Toyota is also looking to extract hydrogen from the methane byproducts derived from animal waste, wastewater treatment plants and landfills.
"Hydrogen is another path to energy independence, security and innovation, expanding how we can move people, goods, information, energy, and society," Choby said.
Finally, Choby provided an introduction of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4414566-1&amp;h=156868976&amp;u=https%3A%2F%2Fpressroom.toyota.com%2Ftoyota-develops-new-fuel-cell-system%2F&amp;a=Toyota%27s+new%2C+next-generation+Gen+3+FC">Toyota's new, next-generation Gen 3 FC</a> system for its North American debut at ACT Expo. The presentation on the new system outlined a preliminary arrival in the U.S. in or after 2027. The Gen 3 FC system has been designed with versatility in mind, with different sizes and power outputs for commercial, heavy trucking and passenger vehicle applications. The next-gen system is expected to be 20% more efficient and 20% more powerful than the current system.

Toyota Motor North America Reaffirms Its Commitment To A Hydrogen Society, Introduces Hydrogen-Related Plans, Investments, Debuts New Fuel Cell Technologies And Products Including North American Debut Of Its Gen 3 FC System

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains First Western Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYFW#NASDAQ">MYFW</a>) with a Outperform and raises the price target from $24 to $26.

MYFW

Keefe, Bruyette & Woods Maintains Outperform on First Western Financial, Raises Price Target to $26

Macro Economic Events

Global

Economics

Watching Shares Of Companies In Spain; Reuters Reports Spanish PM Sanchez Addressed The Nation On Power Outages, Says No Conclusive Information On Causes Of Blackout; Payment Systems Are Working Normally, As Well As Digital Banking

Ant Group&#8217;s <a target="_blank" href="https://www.benzinga.com/topic/alipay" rel="noreferrer noopener">mobile payment platform</a>, Alipay, reported 100 million users for its tap-and-pay service, launched on June 7, 2024.
The service is available in over 400 mainland Chinese cities and supports over 5,000 shopping brands.
Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) introduced the cashless society to China with Alipay&#8217;s QR code and facial recognition function to facilitate payments, similar to Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) Apple Pay, SCMP <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3307968/alipay-leads-chinas-payments-apps-tap-and-pay-service-amassing-100-million-users" rel="noreferrer noopener">reported</a> last Friday.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44871845/paypal-and-bill-holdings-downgraded-by-analyst-amid-rising-tariffs-and-slower-growth-expectations" rel="noreferrer noopener">PayPal, Bill Holdings Downgraded As Analyst &#8216;Loses Confidence&#8217;</a>
Alibaba and Ant Group founder Jack Ma expressed his conviction in the next two decades of Ant at the 20th anniversary of Alipay in December.
Ant Group boosted its global presence through its digital platform, Alipay+.&nbsp;
Ant&#8217;s early global strategy, <a target="_blank" href="https://www.benzinga.com/news/24/05/38641032/jack-ma-backed-ant-groups-alipay-broadens-payment-reach-across-continents-how-its-shaping-global-com" rel="noreferrer noopener">focused on Southeast Asia</a>, saw investments in Singapore&#8217;s 2C2P and South Korea&#8217;s Kakao Pay, which now facilitate their international growth.&nbsp;The company also expanded into emerging markets like Sri Lanka and Cambodia.
It established European partnerships, such as with Italy&#8217;s Tinaba and Nexi, and in the Middle East through Dubai Duty Free. They are focused on large tourism markets like Japan, Thailand, and Singapore while targeting European, Latin American, and Middle Eastern regions to continue growing their merchant coverage.
Prior reports indicated&nbsp;that Mastercard Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) would enhance its&nbsp;cross-border remittance capabilities by partnering with Alipay. Separately, Ant Group tapped Shanghai Fudan Microelectronics to develop integrated circuits for the service.
On Friday, the companies announced a new chip compatible with every smartphone and can work in extreme temperatures from minus 40 to 85 degrees Celsius. Ant Group has placed orders for over 10 million units, with commercialization by the second half of 2025.
Ant Group initiated a global recruitment plan to work on potential breakthroughs in artificial general intelligence (AGI) and next-generation fundamental models.
Ma <a target="_blank" href="https://www.benzinga.com/25/04/44745275/alibaba-bets-big-on-ai-with-new-cloud-tools-as-jack-ma-reemerges-in-company-comeback" rel="noreferrer noopener">relinquished his corporate</a> roles and maintained a low profile since Chinese regulators scrapped Ant Group&#8217;s initial public offering and initiated an antitrust crackdown on domestic giants, including Alibaba. However, he remains a shareholder.
Lately, Ma has frequently appeared at Alibaba offices as the Chinese e-commerce juggernaut eyes a turnaround and aspires to evolve into an AI powerhouse.
At Alipay&#8217;s 20th anniversary in December 2024, Ma emphasized the importance of AI. Ma also attended the symposium chaired by President Xi Jinping in Beijing.
Price Action:&nbsp;BABA stock is down 2.07% at $117.80 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/25/04/45015548/baidu-goes-aggressive-chinas-in-ai-price-war-with-alibaba-deepseek" target="_blank" rel="noreferrer noopener">Baidu Goes Aggressive China&#8217;s In AI Price War With Alibaba, DeepSeek</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Asia

Fintech news covering the emerging Financial Technology services sector

Fintech

Emerging Markets

Tech

Media

AAPL

BABA

Ant Group's Alipay Hits 100 Million Users, Unveils New Chip To Power Fintech Expansion

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) with a Market Perform and lowers the price target from $90 to $77.

Keefe, Bruyette & Woods Maintains Market Perform on Meritage Homes, Lowers Price Target to $77

RBC Capital analyst Brad Heffern maintains Gaming and Leisure Props (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>) with a Outperform and lowers the price target from $56 to $54.

GLPI

RBC Capital Maintains Outperform on Gaming and Leisure Props, Lowers Price Target to $54

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains MidWestOne Financial Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOFG#NASDAQ">MOFG</a>) with a Outperform and lowers the price target from $39 to $38.

MOFG

Keefe, Bruyette & Woods Maintains Outperform on MidWestOne Financial Gr, Lowers Price Target to $38

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Lakeland Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKFN#NASDAQ">LKFN</a>) with a Market Perform and lowers the price target from $69 to $65.

LKFN

Keefe, Bruyette & Woods Maintains Market Perform on Lakeland Financial, Lowers Price Target to $65

Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are pulling back during Monday&#8217;s session by 2.74% to $109.52 after the stock gained some 20% over the past week. The recent rally was fueled by a combination of favorable geopolitical developments, major defense partnerships and strengthening technical signals.
What To Know: Palantir recently broke through a <a href="https://www.benzinga.com/25/04/44985750/stock-of-the-day-is-the-palantir-breakout-finally-here">key resistance level</a> near $97.75, reinforcing the stock's momentum and hinting at the potential for a continued uptrend. The broader market rebound, following <a href="https://www.benzinga.com/25/04/44940900/us-futures-dollar-jump-amid-trumps-latest-comments-on-fed-nikkei-rebounds-to-three-week-high">recent comments</a> from President Donald Trump regarding Federal Reserve leadership, has also provided a supportive backdrop.
Palantir's gains are also being driven by its <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44960295/palantir-shares-climb-after-northrop-grumman-collab-teased-on-x">expanding role</a> in the defense and government technology sectors. The company&#8217;s recently announced partnership with Northrop Grumman on the U.S. Army&#8217;s Tactical Intelligence Targeting Access Node (TITAN) program marks a significant evolution from its traditional software-focused model.
Read Also: <a href="https://www.benzinga.com/trading-ideas/25/04/45020756/trade-deal-or-no-these-2-stocks-will-outperform">Trade Deal Or No, These 2 Stocks Will Outperform</a>
TITAN, a mobile battlefield intelligence platform integrating Palantir's AI with advanced defense hardware, saw its first units delivered to the Army earlier this year.
Additionally, Palantir <a href="https://www.benzinga.com/government/regulations/25/04/44972877/palantir-teams-up-with-google-to-supercharge-fedstart-bringing-ai-tools-to-us-government-agencies-on-secure-cloud">recently announced</a> a collaboration with Google Public Sector to bolster cloud security compliance for federal agencies via its FedStart platform, further cementing its position in defense tech.
Investors are now turning their attention to Palantir's <a href="https://www.benzinga.com/quote/PLTR/earnings">upcoming earnings report</a>, set for May 5. Analyst consensus estimates project EPS of 11 cents on revenue of approximately $799.36 million.
Read Also: <a href="https://www.benzinga.com/news/global/25/04/45038430/massive-power-outages-hit-spain-portugal-snarling-travel-investigations-into-cause-underway">Massive Power Outages Hit Spain, Portugal Snarling Travel: Investigations Into Cause Underway</a>
<h2 class="wp-block-heading">How To Buy PLTR Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Palantir Technologies&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PLTR has a 52-week high of $125.41 and a 52-week low of $20.50.

PLTR

Palantir Stock Is Pulling Back After Rallying 20% Over The Past Week: What's Going On?

RBC Capital analyst Jon Arfstrom maintains First Financial Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFBC#NASDAQ">FFBC</a>) with a Sector Perform and lowers the price target from $30 to $27.

FFBC

RBC Capital Maintains Sector Perform on First Financial Bancorp, Lowers Price Target to $27

Sabre Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>) announced Monday that it will <a href="https://www.benzinga.com/pressreleases/25/04/n45037538/sabre-enters-into-definitive-agreement-to-sell-its-hospitality-solutions-business-unit-to-tpg-for-" target="_blank" rel="noreferrer noopener">sell its Hospitality Solutions business</a> to TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) for $1.1 billion in cash. 
This strategic move aims to streamline operations and sharpen the company&#8217;s focus on core technology platforms.
Sabre expects to receive approximately $960 million in net proceeds after taxes and fees, which it intends to use primarily to reduce debt and strengthen its capital structure.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44634677/goldman-sachs-sees-broad-eps-pressure-across-capital-markets-highlights-brookfield-as-a-standout" target="_blank" rel="noreferrer noopener">Goldman Sachs Sees Broad EPS Pressure Across Capital Markets, Highlights Brookfield As A Standout</a>
Sabre CEO Kurt Ekert praised the team behind Hospitality Solutions for their transformation efforts, adding that the divestiture enables Sabre to concentrate more effectively on its airline IT and travel marketplace operations.
Meanwhile, TPG executives Tim Millikin and Paul Hackwell highlighted their commitment to helping the platform expand and adapt to the evolving needs of the hospitality industry.
Hospitality Solutions, built around Sabre's 2005 acquisition of SynXis, supports over 40% of the world's major hotel brands through its reservation and guest management SaaS platform. The business has steadily expanded, offering products like Retail Studio to help hotels better serve customers.
TPG, known for backing tech carveouts such as Boomi and McAfee, will invest in Hospitality Solutions through TPG Capital. Following the deal's close, expected by the late third quarter of 2025, Sabre will provide temporary transition services to ensure operational continuity during the handover.
TPG held cash and cash equivalents of <a href="https://shareholders.tpg.com/static-files/6b2b43d8-0f5f-4fcc-a9d6-58a2eed31a89" target="_blank" rel="noreferrer noopener">$808.02 million</a> as of Dec. 31, 2024.
Price Action: SABR shares are trading higher by 25.11% at $2.74, and TPG is higher by 0.80% at $46.91 at the last check Monday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/04/45020756/trade-deal-or-no-these-2-stocks-will-outperform">Trade Deal Or No, These 2 Stocks Will Outperform</a></li>
</ul>
Image: Shutterstock

BKNG

CIBR

EXPE

SABR

Sabre Divests Hospitality Arm To TPG For $1.1B, Plans Debt Reduction

Mastercard Announces End-to-End Solutions For Stablecoin Transactions, From Wallets to Checkouts

Keefe, Bruyette &amp; Woods maintains HomeTrust Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTB#NYSE">HTB</a>) with a Outperform and lowers the price target from $43 to $42.

Keefe, Bruyette & Woods Maintains Outperform on HomeTrust Bancshares, Lowers Price Target to $42

RBC Capital analyst Ben Hendrix maintains Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) with a Outperform and raises the price target from $110 to $125.

RBC Capital Maintains Outperform on Encompass Health, Raises Price Target to $125

Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Corning will report an earnings per share (EPS) of $0.51. 
Anticipation surrounds Corning's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 0.38% increase in the share price the next day.
Here's a look at Corning's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.56</td>
<td>0.52</td>
<td>0.46</td>
<td>0.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.54</td>
<td>0.47</td>
<td>0.38</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745856199_0.png" alt="eps graph" />
<h3>Corning Share Price Analysis</h3>
Shares of Corning were trading at $44.18 as of April 25. Over the last 52-week period, shares are up 31.28%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Corning</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Corning.
The consensus rating for Corning is Buy, based on 5 analyst ratings. With an average one-year price target of $56.0, there's a potential 26.75% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Coherent, Littelfuse and Belden, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Coherent, with an average 1-year price target of $100.85, suggesting a potential 128.27% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Littelfuse, with an average 1-year price target of $236.0, suggesting a potential 434.18% upside.</li>
<li>Analysts currently favor an Buy trajectory for Belden, with an average 1-year price target of $127.0, suggesting a potential 187.46% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for Coherent, Littelfuse and Belden, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corning</td>
<td>Buy</td>
<td>16.93%</td>
<td>$1.20B</td>
<td>2.85%</td>
</tr>
<tr>
<td>Coherent</td>
<td>Buy</td>
<td>26.80%</td>
<td>$509.35M</td>
<td>1.33%</td>
</tr>
<tr>
<td>Littelfuse</td>
<td>Neutral</td>
<td>-0.81%</td>
<td>$176.84M</td>
<td>-2.08%</td>
</tr>
<tr>
<td>Belden</td>
<td>Buy</td>
<td>20.83%</td>
<td>$249.82M</td>
<td>4.62%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Corning ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. Corning is at the top for Return on Equity.
<h3>All You Need to Know About Corning</h3>
Corning is a leader in materials science, specializing in the production of glass, ceramics, and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
<h3>Corning: A Financial Overview</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Corning showcased positive performance, achieving a revenue growth rate of 16.93% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.85%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.85%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Corning's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.11% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.76, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/GLW/earnings">To track all earnings releases for Corning visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

What to Expect from Corning's Earnings

Biotech

General

SOPH

Sophia Genetics Expands Collaboration With AstraZeneca To Accelerate The Deployment Of MSK-ACCESS Powered With SOPHiA DDM Globally

Logitech International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Logitech International will report an earnings per share (EPS) of $0.86. 
Investors in Logitech International are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.23, leading to a 4.12% increase in the share price on the subsequent day.
Here's a look at Logitech International's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.36</td>
<td>0.99</td>
<td>0.86</td>
<td>0.63</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.59</td>
<td>1.20</td>
<td>1.13</td>
<td>0.99</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-9.0%</td>
<td>-3.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745856187_0.png" alt="eps graph" />
<h3>Tracking Logitech International's Stock Performance</h3>
Shares of Logitech International were trading at $77.785 as of April 25. Over the last 52-week period, shares are down 0.8%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LOGI/earnings">To track all earnings releases for Logitech International visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LOGI

A Look at Logitech International's Upcoming Earnings Report

In 1976, The Wall Street Journal published an opinion column that ascribed an astounding revelation to one of the greatest minds in history. Albert Einstein was asked what he surmised to be man's greatest invention.
He didn't answer with the wheel or electricity. He replied: "Compound interest."
Whether he actually said that is up for debate, but the truth behind the quote is undeniable.
It sounds simple. It is simple. But most investors still get it wrong.
Compounding, Part 1: Interest on your interest
Compound interest is money's version of a perpetual motion machine. You earn interest not just on your principal, but on your interest. And then interest on that. Over and over.
It's how a modest investment return can snowball a portfolio into something impressive—if you let it.
But here's where many investors trip: they become obsessed with chasing higher returns.
Beating the market feels like winning. But building wealth isn't about winning annual benchmark comparisons. Given your risk tolerance and emotional fortitude, it's about growing your portfolio to its maximum potential.
Ask yourself: Would you rather beat the market in some years and end up with $1 million…or underperform in many years but wind up with $1.2 million?
You can't spend bragging rights in retirement.
Compounding, Part 2: Time—the hidden superpower
The longer your money stays invested, the harder compounding works as your silent partner in wealth creation.
Warren Buffett is unquestionably a skilled investor, but his superpower is time. He has been a good investor, a patient investor, for eight decades.
The time component of compounding is the rocket fuel that took Buffett's wealth accumulation into the stratosphere. It's why his first billion came after age 55, and 97% of his wealth came after his 65th birthday.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="1024" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/28111600/Warren-Buffett-Net-Worth-version-2-1024x1024.jpg" alt="" class="wp-image-11698" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/28111600/Warren-Buffett-Net-Worth-version-2-1024x1024.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/28111600/Warren-Buffett-Net-Worth-version-2-300x300.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/28111600/Warren-Buffett-Net-Worth-version-2-150x150.jpg 150w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/28111600/Warren-Buffett-Net-Worth-version-2-768x768.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/28111600/Warren-Buffett-Net-Worth-version-2.jpg 1080w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Charlie Munger put it bluntly: "The first rule of compounding is to never interrupt it unnecessarily." And how do investors usually interrupt it? By chasing higher returns. That's like taking a chainsaw to a bonsai tree because it's growing too slow.
Peter Lynch ran Fidelity's Magellan Fund from 1977 to 1990, posting an incredible 29.2% average annual return—nearly double the S&amp;P 500. You'd think investors would've made a fortune, right?
Nope. During that remarkable run under Lynch, the average investor in the fund reportedly lost money. Why? They bought in late after big run-ups, panic-sold after downturns, and sat in cash looking for a different "market winner" when they should have stayed the course.
They turned a compounding machine into a vending machine, and it ate their dollar bills. (The Magellan story is not an isolated tale. See <a href="https://cosmodestefano.substack.com/p/winning-the-long-game-investing-requires">here</a> for more on the prevalence of this investor performance gap.)
Compounding, Part 3: New money—the force multiplier
The most underrated lever in wealth-building isn't returns or timing. It's you. Specifically, your monthly contributions.
Let's say you start with $1,000 and earn 10% annually. After five years, you'll have a little over $1,600. Not bad.
But now imagine you also invest $100 every month. After those five years, your portfolio swells to nearly $10,000. That's a 500% leap — not from better performance, but from steady, boring, powerful consistency.
In the first 10-15 years of your wealth-building journey, how much you invest matters more than how well you invest.
But what if you could double your return? Here's how the math shakes out:
<ul>
<li>Save 20% of your salary and earn 5% annually, and your portfolio balance surpasses your salary in about 4.5 years.</li>
<li>Double your return to 10%? You get there just five months faster.</li>
</ul>
The early innings aren't won by clever trades or market timing. They're won by habit and hustle—those monthly contributions. (Later, once your portfolio has real weight behind it, returns start pulling more of the load.)
The wealth accumulation trifecta
Intuitively, pursuing the highest returns feels like the best way to maximize wealth. However, once investors consider the importance of both time and monthly contributions, they realize that maximizing annual returns and maximizing wealth are two different concepts.
To build wealth, you don't need to swing for the fences. You need to stack three simple habits:
<ol>
<li>Earn reasonable, repeatable returns</li>
<li>Let time do its quiet work, uninterrupted</li>
<li>Keep adding fresh cash every month</li>
</ol>
That's the trifecta. No gimmicks. No get-rich-quick trades. Just boring, beautiful compounding.
Don't let the early years of compounding fool you. They feel slow, almost like nothing's happening. But that's how compounding starts. Quiet. Invisible. Then&#8230;exponential.
Stay patient. Stick to your plan. Trust that compounding portfolio growth does work.
Review your investment strategy this week with these three principles in mind. As the current markets bounce around and headlines scream, lean into discipline, not drama.
While others chase performance like caffeinated cats in a laser pointer factory, you'll quietly build unstoppable momentum.
You don't need to be the first across the wealth accumulation finish line, but by embracing all three components of compounding, you can help ensure that you do indeed cross it.
As always, invest often and wisely. Thank you for reading.
&#x2A;&#x2A;
My book, <a href="https://geni.us/wealthyourwaypb" target="_blank" rel="noreferrer noopener">Wealth Your Way,&nbsp;is available on Amazon</a>, and consider subscribing to <a href="https://cosmodestefano.substack.com/">my free newsletter</a>.
The content is for informational purposes only. It is not intended to be nor should it be construed as legal, tax, investment, financial, or other advice. It is merely my own random thoughts.
<figure class="wp-block-image size-full is-resized"><a href="https://geni.us/wealthyourwaypb"><img loading="lazy" decoding="async" width="472" height="538" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/31105237/WYW-with-2025-IPA-winner-and-store-logos.jpg" alt="" class="wp-image-9279" style="width:472px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/31105237/WYW-with-2025-IPA-winner-and-store-logos.jpg 472w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/31105237/WYW-with-2025-IPA-winner-and-store-logos-263x300.jpg 263w" sizes="(max-width: 472px) 100vw, 472px" /></a></figure>
The best way to spread the word about a book you enjoyed is to leave an honest review. Thank you for taking the time to&nbsp;<a href="https://www.amazon.com/review/create-review/?ie=UTF8&amp;channel=glance-detail&amp;asin=B09XP7383J">click here</a>&nbsp;and post your review of&nbsp;Wealth Your Way. Your review will help other readers explore their own path to a richer, happier life!

Long Ideas

Education

Opinion

Stop Chasing Returns. Start Building Wealth.

Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Laboratory Corp will report an earnings per share (EPS) of $3.73. 
Anticipation surrounds Laboratory Corp's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.06, leading to a 0.59% drop in the share price the following trading session.
Here's a look at Laboratory Corp's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>3.39</td>
<td>3.49</td>
<td>3.78</td>
<td>3.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.45</td>
<td>3.50</td>
<td>3.94</td>
<td>3.68</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745856181_0.png" alt="eps graph" />
<h3>Performance of Laboratory Corp Shares</h3>
Shares of Laboratory Corp were trading at $228.31 as of April 25. Over the last 52-week period, shares are up 13.57%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Laboratory Corp</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Laboratory Corp.
The consensus rating for Laboratory Corp is Buy, derived from 9 analyst ratings. An average one-year price target of $273.0 implies a potential 19.57% upside.
<h3>Peer Ratings Comparison</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Quest Diagnostics, DaVita and Chemed, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Quest Diagnostics, with an average 1-year price target of $183.86, suggesting a potential 19.47% downside.</li>
<li>Analysts currently favor an Neutral trajectory for DaVita, with an average 1-year price target of $169.0, suggesting a potential 25.98% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Chemed, with an average 1-year price target of $670.5, suggesting a potential 193.68% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Quest Diagnostics, DaVita and Chemed, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labcorp Hldgs</td>
<td>Buy</td>
<td>9.76%</td>
<td>$896.30M</td>
<td>1.77%</td>
</tr>
<tr>
<td>Quest Diagnostics</td>
<td>Neutral</td>
<td>12.09%</td>
<td>$863M</td>
<td>3.20%</td>
</tr>
<tr>
<td>DaVita</td>
<td>Neutral</td>
<td>4.73%</td>
<td>$1.07B</td>
<td>102.13%</td>
</tr>
<tr>
<td>Chemed</td>
<td>Outperform</td>
<td>1.09%</td>
<td>$234.12M</td>
<td>6.24%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Laboratory Corp ranks highest in gross profit among its peers. It is in the middle for consensus rating and revenue growth. However, it has the lowest return on equity compared to the other companies analyzed.
<h3>Get to Know Laboratory Corp Better</h3>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Laboratory Corp's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Laboratory Corp showcased positive performance, achieving a revenue growth rate of 9.76% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Laboratory Corp's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.31% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Laboratory Corp's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.77%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Laboratory Corp's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.78%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Laboratory Corp's debt-to-equity ratio is below the industry average. With a ratio of 0.9, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/LH/earnings">To track all earnings releases for Laboratory Corp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Laboratory Corporation Of America Holdings

Earnings Preview: Laboratory Corp

Press Releases

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges – More Stocks Inside

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Health Care

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Management

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Financing

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

EVAX

GSIT

IVVD

KAPA

PRSO

QNTM

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Agenus

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Biomea Fusion

Climb Bio

Caribou Biosciences

CervoMed

Elicio Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

IGM Biosciences

I-MAB

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Jasper Therapeutics, Inc. - Class A Common Stock

Comments

Invivyd

Invivyd (IVVD) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル